Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation

Antibody‐mediated rejection (AMR) is a major barrier preventing successful discordant organ xenotransplantation, but it also occurs in allotransplantation due to anti‐HLA antibodies. Symptomatic acute AMR is rare after heart allograft but carries a high risk of mortality, especially >1 year after...

Descripción completa

Detalles Bibliográficos
Autores principales: Yerly, Patrick, Rotman, Samuel, Regamey, Julien, Aubert, Vincent, Aur, Stefania, Kirsch, Matthias, Hullin, Roger, Pascual, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285545/
https://www.ncbi.nlm.nih.gov/pubmed/35001433
http://dx.doi.org/10.1111/xen.12726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285545/
https://www.ncbi.nlm.nih.gov/pubmed/35001433
http://dx.doi.org/10.1111/xen.12726

Ejemplares similares